Evaluation of the Effectiveness of Eliquis ® (Apixaban) Risk Minimization Tools in European Economic Area (EEA) Countries

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Stroke, Systemic Embolism, VTEt and VTEp

Study type: Observational

Funder types: Industry

Identifiers

NCT02339818

CV185-365

Details and patient eligibility

About

The main purpose is to evaluate the effectiveness of the Eliquis® (apixaban) Prescriber Guide and Patient Alert Card in terms knowledge of the important identified risk of bleeding associated with Eliquis treatment communicated by the RM tools.

Full description

Observational Model, Other- This is a non-interventional, cross-sectional study in the EEA involving representative samples of HCPs who treat patients with Eliquis, as well as patients treated with Eliquis. This study will be facilitated via web-based surveys used to evaluate the effectiveness of the Eliquis Prescribe Guide and Patient Alert Card as risk management tools.

Enrollment: 384 Health Care Professions (HCPs) and 192 Patients

Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE in adults (VTEt)

Prevention of VTE in adult patients knee replacement surgery (VTEp)

Enrollment: 126 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• HCP must have been involved in the treatment of at least one patient with Eliquis for any approved indication
• Patients must have taken Eliquis for any approved indication

Trial design

126 participants in 2 patient groups

HCPs

Description:

HCPs involved in using Eliquis (apixaban)

Patients

Description:

Patients taking Eliquis for any of the three currently approved indications